Blue Earth Diagnostics   Report issue

Contributed to NME For profit Phase 2 Phase 3 Phase 4
Founded: Oxford United Kingdom (2014)
Status: Acquired by Bracco (2019)

Organization Overview

First Clinical Trial
2015
NCT02443571
First Marketed Drug
2016
Fluciclovine (Axumin)
First NDA Approval
2016
Fluciclovine (Axumin)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BLUE EARTH | Blue Earth Diagnostics | Blue Earth Diagnostics Ltd